MAIA Biotechnology, Inc.
(MAIA)
Add Watchlist
3.28 USD -0.04
Closed: 03 May, 3:55 pm
Symbol MAIA
Market Cap 44.6M
Price 3.28
Open 3.11
52-wk High 3.59
50 Day Avg 2.03
Earnings Announcement 2023-08-28
Website https://www.MAIABiotech.com
Name MAIA Biotechnology, Inc.
Shares Outstanding 13,625,900
Change % 4.127%
Low 3.11
52-wk Low 0.82
200 Day Avg 1.76
Last Dividend 0.00
Exchange AMEX
Volume 405,249
Previous Close 3.15
High 3.37
EPS -1.48
PE -2.22
Avg Volume 354,074
CUSIP 552641102
MAIA Biotechnology, Inc. Outlook
Description MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Currency USD
ISIN US5526411021
Industry Biotechnology
Changes 0.13
CUSIP 552641102
Range 0.82 - 3.59
Beta 0.18
CIK 0001878313

MAIA Biotechnology, Inc. News

05-Apr-2024 8:01 AM

MAIA Biotechnology to Present at Two Investor Conferences in April 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Two Investor Conferences in April 2024.

05-Jan-2024 8:00 AM

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024.

04-Jan-2024 9:04 AM

MAIA Biotechnology: Significantly Undervalued With Novel Mechanism And Impressive Early Data

Lead asset THIO has a unique telomere-targeting mechanism and has reported impressive preliminary results in NSCLC. THIO's 90%+ disease control rate in second- and third-line NSCLC is an improvement over current standard of care. Plans to pursue accelerated approval in NSCLC in 2025 and has the potential to become a new standard of care.

01-Dec-2023 11:18 AM

Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now

MAIA Biotechnology, Inc. (MAIA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

19-Oct-2023 8:35 AM

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at ESMO Congress 2023.

01-Jul-2023 2:41 AM

MAIA Biotechnology: Progress In The THIO-101 Trial Sets Up A 2023 Catalyst

MAIA's THIO-101 trial of 6-thio-2-deoxyguanosine in non-small cell lung cancer had enrolled 29 patients as of a June 20 update from the company. The first two patients in the trial have achieved continued survival at 10 and 11 months following the start of treatment. MAIA has enough cash to make it to an update from the trial, but another cash raise could be ahead.

29-Jun-2023 4:49 PM

7 Up-and-Coming Stocks to Buy for the Next Decade

In arguably most cases involving expert financial advice, you will encounter guidance toward established enterprises, not up-and-coming stocks to buy. While the latter category certainly dials up the heat in terms of overall sexiness, some folks just can't handle adventurous portfolios.

12-Apr-2023 3:57 PM

MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study

MAIA Biotechnology (MAIA) gains on encouraging data on lead candidate from Part A of its mid-stage study in advanced non-small cell lung cancer.

05-Jan-2023 8:00 AM

MAIA Biotechnology to Participate in Four Upcoming Investor Conferences

CHICAGO--( BUSINESS WIRE )--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”) announced today that the management team will participate in the four upcoming investor conferences as follows:

29-Sep-2022 9:01 AM

MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that it will present the results of a study of the anticancer agent 6-thio-dG (THIO) in hepatocellular carcinoma (HCC) in vitro and in vivo models at the EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics. The symposium is taking place Oct. 26-28, 2022

06-Sep-2022 8:00 AM

MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA,” “the Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical Oncology (ESMO) Congress 2022, being held from September 9th to 13th in Paris, France. THIO is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small ce